COVID19 News

The leading antiviral treatments for a person with either a SARS-CoV-2 coronavirus infection or the disease is causes, COVID-19, became more accessible today.
The U.S. Food and Drug Administration (FDA) notified Pfizer Inc. and Merck Sharp & Dohme LLC on February 1, 2023, it has issued revised emergency Use Authorization (EAU) #105 and #108.

While Influenza virus infections declined globally during the early days of the COVID-19 pandemic, a recent study found an increased risk of household transmission of influenza A(H3N2) in the 2021-2022 flu season compared with prepandemic seasons.
More frequent interaction with an infected person would be expected to increase infection risk, and in 2021-2022, household contacts reported spending more time in the same room with others.

The combination of influenza, COVID-19, and respiratory syncytial virus (RSV) severely strained hospitals this winter.
Although many people infected with these airborne viruses will recover, many develop pneumonia and require hospital treatment. 
Pneumonia is an infection of the lungs that viruses, bacteria, or fungi can cause. And it causes air sacs to fill up, making it harder to breathe and for organs to get enough oxygen.

The peer-review journal Lancet recently published a study that found a vaccine candidate targeting the Marburg virus (MARV) was safe and induced an immune response in a small, first-in-human clinical trial. 
The known as cAd3-Marburg vaccine, developed by researchers at the U.S. National Institute of Allergy and Infectious Diseases (NIAID), could become an essential tool if approved to respond to future Marburg virus outbreaks.